The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.
An article from
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.
Published May 27, 2026
The FDA has extended its review of camizestrant, a drug AstraZeneca is developing for breast cancer.
Sarah Silbiger via Getty Images
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank…
This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with a…
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival…
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s…
Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo…
Kailera touts early weight loss data; Arrowhead takes a shot at the same obesity target as Wave; FDA delays AstraZeneca’s…
